

Patterned progression of gut microbiota associated with necrotizing enterocolitis and late onset sepsis in preterm infants: a prospective study in a Chinese neonatal intensive care unit

Jiayi Liu¹, Yuqing Li¹, Yi Feng¹, Liya Pan¹, Zhoulonglong Xie², Zhilong Yan², Li Zhang³, Mingkun Li^{3,4}, Jianhua Zhao⁵, Jianhua Sun⁶, and Li Hong¹

¹Department of Clinical Nutrition, Shanghai Children's Medical Center, School of Medicine Shanghai Jiao Tong University, Shanghai, China

²Department of Surgery, Shanghai Children's Medical Center, School of Medicine Shanghai Jiao Tong University, Shanghai, China

³Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, China Academy of Science, Beijing, China

⁴Center for Excellence in Animal Evolution and Genetics, Chinese Academy of Sciences, Kunming, China

⁵Shanghai Majorbio Bio-Pharm Technology Co., Ltd, Shanghai, China

⁶Department of Neonatology, Shanghai Children's Medical Center, School of Medicine Shanghai Jiao Tong University, Shanghai, China

Corresponding author:

Li Hong¹

Email address: hongli@scmc.com.cn

ABSTRACT

Necrotizing enterocolitis (NEC) and late-onset sepsis(LOS) are two common premature birth complications with high morbidity and mortality. Recent studies in Europe and America have linked gut microbiota dysbiosis to their etiology. However, similar studies in Asian populations remain scant. In this pilot study, we profiled gut microbiota of 24 Chinese preterm infants from birth till death or discharge from NICU. Four of them developed NEC and three developed LOS. Unexpectedly, we detected highly-diversified microbiota with similar compositions in all patients shortly after birth. However, as patients aged, the microbial diversities in case groups differed significantly from that of the control group. These differences emerged after the third day of life and persisted throughout the course of both NEC and LOS. Using a Zero-Inflated Beta Regression Model with Random Effects (ZIBR), we detected higher *Bacillus* ($p = 0.032$) and *Solibacillus* ($p = 0.047$) before the onset of NEC and LOS. During NEC progression, *Enterococcus*, *Streptococcus* and *Peptoclostridium* were the dominant genera while during LOS progression, *Klebsiella* was the only dominant genus that was also detected by the diagnostic hemoculture. These results warrant further studies to identify causative microbial patterns and underlying mechanisms.

INTRODUCTION

The gut microbiota is a crucial contributor to human health. Imbalance of the microbial community, termed dysbiosis, is associated with various diseases, such as obesity and diabetes(Bouter et al., 2017; Rosenbaum et al., 2015; Winer et al., 2016; Cani, 2019; Zmora et al., 2019), immunity-related diseases(Vogelzang et al., 2018; Pronovost and Hsiao, 2019; Vatanen et al., 2016), neurodevelopmental disorders(Sampson and Mazmanian, 2015; Pronovost and Hsiao, 2019), cardiovascular diseases(Tang et al., 2017; Jie et al.,

2017; Jonsson and Bäckhed, 2017) and cancers(Gagliani et al., 2014; Irrazábal et al., 2014; Sears and Garrett, 2014).

The microbiota in newborn infants undergoes dynamic changes in composition, abundance and diversity before reaching homeostasis at around three years of age(Yatsunenko et al., 2012; Bäckhed et al., 2015; Stewart et al., 2018). Temporal colonization pattern of the intestinal microbiota during early stages of life may have an important contribution to the long term health of an individual. Early life microbiota disruption had been associated with the development of metabolic and immunological diseases such as Type I diabetes(Giongo et al., 2011; Vatanen et al., 2018), asthma(Stokholm et al., 2018) and allergies(Madan et al., 2012a; Savage et al., 2018).

In preterm infants, common medical practices including Cesarean delivery, formula feeding, sterile incubator nursing and extensive use of broad-spectrum antibiotics may limit the normal microbiota acquisition and development(La Rosa et al., 2014; Shin et al., 2015; Deweerdt, 2018). Resultant abnormal microbiota colonization in the gut may then contribute complications such as necrotizing enterocolitis (NEC) and late onset sepsis (LOS)(Sharon et al., 2015; Cernada et al., 2016).

Necrotizing enterocolitis is characterized by rapid ischemic necrosis of intestinal mucosa, resulting in high morbidity (2% - 7%) and mortality (15% - 30%)(Neu and Walker, 2011; Stoll et al., 2015). Its etiology remains largely unknown and likely to be multi-factorial. Previous studies in European and American countries have associated microbial dysbiosis to NEC onset. Reduction in microbiota diversity and unusual species colonization were observed in NEC patients(Jacquot et al., 2011; Warner et al., 2016). No causative species have been identified so far. However, an increase in Proteobacteria phyla and a decrease in Firmicutes were observed before NEC onset(Mai et al., 2011; Zhou et al., 2015). Besides, blooming of *Gammaproteobacteria* and under-representation of *Negativicutes* were associated with disease progression(Warner et al., 2016).

Late onset sepsis (LOS) is another common life-threatening disease for preterm infants. It is commonly defined as a systemic infection with the isolation of pathogenic bacteria from the bloodstream after 72 hours of life(Rao et al., 2016; Pickering et al., 2012). Preterm infants have immature gastrointestinal and immune systems. Therefore, it is easier for pathogenic bacteria or bacterial toxins that can cause systemic inflammation to enter the bloodstream(Schwartz et al., 2003; Bezirtzoglou et al., 2011; Cernada et al., 2016; Sharon et al., 2015; Korpela et al., 2018), thus making the intestine a potential source of infections and inflammation. Previous studies showed that the LOS patients' gut microbiota was less diversified, and dominated by *Staphylococci* and *Enterobacter* but underrepresented by probiotic *Bifidobacteria*(Madan et al., 2012b; Tarr and Warner, 2016; Stewart et al., 2017; Korpela et al., 2018; Ficara et al., 2018).

NEC and LOS are two major causes of morbidity and mortality in preterm infants worldwide and have been exerting economic burdens on healthcare costs(Johnson et al., 2013, 2014; Mowitz et al., 2018). Although early recognition and treatment regimen has improved clinical outcomes, both diseases still account for morbidities in NICU survivors(Hintz et al., 2005; Zonnenberg et al., 2019; Shah et al., 2015). In China, the rate of preterm birth is as high as 7.1%(Blencowe et al., 2012) and continuous improvements in neonatal health care have greatly improved the survival of preterm infants. However, the risk of developing NEC and LOS increases as well. Elucidating their pathogenesis and developing preventive strategies would greatly benefit the health of preterm infants. Motivated by this, we carried out this longitudinal pilot study to profile the microbiota of Chinese preterm NEC and LOS patients, with the aim to examine if similar alterations in microbiota correlate with the onset and progression among Chinese patients. Consistent with previous studies in Western countries, we observed lower bacterial diversity among Chinese NEC and LOS patients. In contrast, we found that the Chinese patients in our cohort showed different bacterial compositions.

METHODS

Ethics

This study was approved by the joint committee of ethics of Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine (SCMCIRB-K2013022). Detailed written informed consent was obtained from parents before enrolment.

Patients

Newly born preterm infants with a gestational age less than 33 weeks and birth weight over 950g were enrolled from Neonatal Intensive Care Unit (NICU) at Shanghai Children's Medical Center from July 2013

to December 2014. The exclusion criteria were 1) diagnosed with early-onset sepsis, 2) hepatic diseases, 3) renal impairment ($\text{Cr} > 88 \mu\text{M}$), 4) diagnosed with intestinal obstruction, 5) in foreseeable need of major cardiovascular or abdominal surgeries (except for male circumcision or PDA ligation), 6) estimated parenteral support to supply over 50% of daily caloric intake for more than four days, 7) given intravenous antibiotics administration (except prophylactic regimen of cefotaxime, piperacillin-tazobactam and/or metronidazole), 8) history of oral antibiotics administration, 9) grossly bloody stools at admission, and 10) over five days old.

NEC cases were defined as infants who met the criteria for Stage II and Stage III NEC diagnosis (Bell et al., 1978), including radiographic intestinal dilation, ileus, pneumatosis intestinalis, and/or absent bowel sounds with or without abdominal tenderness, and/or mild metabolic acidosis and thrombocytopenia. An LOS case was defined if an infant 1) had a positive hemoculture or other suspicious loci of infection after 72 hours of life, or 2) presented with septic signs/symptoms reviewed and diagnosed independently by at least two neonatologists, and had been responding well with advanced antibiotics (e.g., Meropenem) after diagnosis. Infants with no infectious complications were regarded as controls.

Sample collection and handling

Fecal sample collection started from neonatal meconium until death or discharge, whichever came first. Although we intended to collect fecal samples every day, due to working shifts and flexible clinical scheduling, we set seven days as the maximum interval between two collections from every infant. Every sample was collected from infants' diaper with a sterile spatula into cryogenic vials within 30 minutes of defecation. Then the sample was immediately placed on dry ice and stored at -80°C within 30 minutes without additives. All samples were collected and stored before knowing the diagnosis of respective patients.

DNA extraction and quality control amplification and 16s rRNA gene sequencing

Microbial genomic DNA was isolated from each fecal specimen using the E.Z.N.A.® Soil DNA Kit (Omega Bio-Tek, Norcross, GA, U.S.) according to the manufacturer's protocols. The concentration and purity of the DNA were determined by NanoDrop 2000 UV-vis spectrophotometer (Thermo Scientific, Wilmington, USA), and the DNA quality was checked by 1% agarose gel electrophoresis.

Broad-range PCR and High-throughput Sequencing of 16s rRNA gene amplicons

The V3-V4 hypervariable regions of the bacterial 16S rRNA gene were amplified by PCR from each sample using bacterial/archaeal primers 338F (5'-ACTCCTACGGGAGGCAGCAG-3') and 806R (5'-GGACTACHVGG GTWTCTAAT-3') using a thermocycler PCR system (GeneAmp 9700, ABI, USA). The PCR reactions were as follows: 3 min of denaturation at 95°C , 27 cycles of 30 s at 95°C , 30 s annealing at 55°C and 45 s elongation at 72°C , and a final extension at 72°C for 10 min. The PCR reactions were performed in triplicate, with each 20 μL mixture containing 4 μL 5X FastPfu Buffer, 2 μL 2.5 mM dNTPs, 0.8 μL of each primer (5 μM), 0.4 μL FastPfu Polymerase (TransGen Biotech, Beijing, China) and 10 ng template DNA. PCR products were separated from impurities and genomic DNA by running in 2% agarose gels. The PCR bands were further purified using the AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, USA), and quantified using QuantiFluor™-ST (Promega, USA) according to the manufacturer's protocols. Equimolar amounts of purified amplicons were pooled and paired ended sequenced (2 x 300) on an Illumina MiSeq platform (Illumina, San Diego, USA) according to the standard protocols of Majorbio Bio-Pharm Technology Co. Ltd. (Shanghai, China). The reads were de-multiplexed using the Illumina software and separate FASTQ files were generated for each specimen and deposited to the Sequence Read Archive NCBI under the BioProject accession PRJNA470548. Another public archive repository is available at figshare doi: 10.6084/m9.figshare.7205102

Raw Data Processing

Raw data were processed according to the standard protocols provided by Majorbio Bio-Pharm Technology Co. Ltd. (Shanghai, China) as previously described (Liu et al., 2018; Wang et al., 2018). In short, raw sequencing data was first de-multiplexed. Sequence reads were then subjected to quality filtering utilizing Trimmomatic software (Bolger et al., 2014) and were truncated at any site with a Phred score < 20 over a 50bp-sized window. Barcode matching with the primer mismatch from 0 to 2 nucleotides was adopted and reads containing ambiguous characters were removed. After trimming, FLASH (Fast Length Adjustment of Short Read) (Magoč and Salzberg, 2011), a read pre-processing software, assembled and merged the

148 paired-end reads from fragments and generated >10 bp overlapped, with the dead match ratio of 0.2.
149 Unassembled reads were discarded. From the 192 fecal samples sequenced, a total of 7,472,400 optimized
150 V3-V4 tags of 16s rRNA gene sequences were generated (Table S1).

151 To unbiasedly compare all the samples at the same sequencing depth, the "sub.sample" command
152 of mothur program (version 1.30.1) (Schloss et al., 2009) was used for normalization to the smallest
153 sample size. Chimera was detected and removed by UCHIME Algorithm. The effective reads were
154 then sorted by cluster size and processed using Operational Taxonomic Units (OTUs) with 97% simi-
155 larity cutoff UPARSE-OTU algorithm (implementing "cluster_otus" command) (Edgar, 2013) in USE-
156 ARCH (v10) (UPARSE version 7.1). The taxonomy of each 16S rRNA gene sequence was analyzed by
157 RDP Classifier algorithm (Wang et al., 2007) against the Silva (SSU128) 16S rRNA database (Quast et al.,
158 2012) using confidence threshold of 70%. Each sequence was assigned the taxonomy by QIIME (Caporaso
159 et al., 2010). The representative sequences were allocated phylogenetically down to the domain, phylum,
160 class, order, family, and genus levels (Table S2). The relative abundance of a given taxonomic group was
161 calculated as the percentage of assigned sequences over total sequences.

162 Within-sample diversity (alpha diversity), including Shannon index and observed species richness
163 (Sobs), was obtained using the "summary.single" command of mothur program (version 1.30.1) (Schloss
164 et al., 2009). Between-sample diversity (beta diversity) was obtained by calculating weighted UniFrac
165 distances between samples.

166 **Statistical and Bioinformatics Analyses**

167 ***Demographics and Clinical Sample comparisons***

168 Kruskal-Wallis test and Wilcoxon rank-sum test were used to identify statistically significant differences in
169 continuous variables, including gestational age, birth weight, age at diagnosis and length of hospitalization.
170 The χ^2 , or Fisher's exact test was used to identify differences in gender composition. α level was
171 considered 0.05 for all statistical tests. Other statistical analyses not involving microbiome 16s rRNA
172 sequencing data were performed using the "stats" package in R (v.3.5.1).

173 ***Microbiota and Bioinformatics Analyses***

174 **Disease-related Time Interval Definition** Considering that the sampling and disease onset time for
175 each patient were not identical, to illustrate the continuous longitudinal and repeated nature of the sampling
176 and its relationship with onset and progression of diseases, we divided the sampling span into seven time
177 intervals:

- 178 1. early post-partum (EPP): within 3 days after birth
- 179 2. early pre-onset (EPO): from the end of EPP to at least four days before disease onset
- 180 3. late pre-onset (LPO): from the end of EPO to the disease onset; for control group patients, the
181 equivalent onset time is set at the 16th day of life, as is the average diagnosis age of NEC and LOS
182 groups.
- 183 4. early disease (ED): the first third interval of the whole disease span; for the control group, the
184 equivalent ED interval is from day 16 to discharge.
- 185 5. middle disease (MD): the middle third interval of disease span
- 186 6. late disease (LD): the last third interval of disease span
- 187 7. post disease (PD): from the end of disease to discharge time-point

188 **Modeling Strategies for Comparisons** To compare the dynamics of microbiota diversity and relative
189 taxonomic abundance preceding the disease, we applied the EPP, EPO, LPO and ED interval among all
190 patients into our model or comparisons.

191 **Diversity Analyses** Kruskal Wallis tests were used to compare the differences in overall alpha diversity.
192 The Mann-Whitney U test was then applied to compare two adjacent time intervals. Differences in alpha
193 diversity over time were analyzed by a two-way repeated measures ANOVA, with the time interval
194 (EPP, EPO, LPO, ED, MD, LD, PD) as a within-subject factor and the group (NEC, LOS, control) as a
195 between-subject factor. If more than one sample of a patient were collected within a time interval, the
196 average of the α diversity indices was used as one data point.

197 **Taxonomy Comparisons** Zero-Inflated Beta Regression Model with Random Effects (ZIBR) and
198 Linear Mixed-effects Model (LME) were used to test the association between OTU relative abundance
199 and clinical covariates (disease-related time intervals) for longitudinal microbiome data (Chen and Li,

200 2016). *ZIBR* and *nlme*(Pinheiro et al., 2018) R packages were utilized for each model. If more than one
201 sample of a patients were collected within a time interval, the average of relative abundance of each genus
202 was used.

203 **Scripts and Figures Archiving**

204 Figures were generated with the "*ggpubr*"(Kassambara, 2017), "*ggplot2*"(Wickham, 2016) and "*ggsci*"(Xiao,
205 2018) packages using R(v.3.5.1). RScripts for analyses as well as input and output files are available at
206 our GitHub repository.

207 **RESULTS**

208 **Patients characteristics**

209 From July 2013 to December 2014, a total of 130 preterm infants admitted to the neonatal intensive
210 care unit (NICU) of Shanghai Children's Medical Center met the criteria of our study and a total of
211 1698 samples were collected. 192 fecal samples from 24 well-sampled preterm infants were sequenced.
212 Four subsequently developed NEC (2 in stage IIA and 2 in stage IIB) and three developed LOS (2 with
213 positive hemoculture of *Klebsiella pneumoniae*; the other one was diagnosed upon sepsis-related signs
214 and symptoms, lab test of white blood cells >20 cells/microL and her effective reaction to vancomycin).
215 The remaining 17 served as matched controls (Figure1, Table S3). Fecal samples were collected between
216 days 1 and 69 of life. Numbers of samples collected and interval of sampling varied among patients but
217 met our preset criteria of less than 7 days between sampling. The average number of sample collected for
218 NEC, LOS and control patients was 11, 14 and 6 respectively. The number of samples per patient was
219 higher in the NEC and LOS groups because the severity of the disease required longer hospitalization (p
220 = 0.046).

221 All 24 infants profiled were delivered by Cesarean section, fed on infant formula and prescribed with
222 prophylactic antibiotics regimen (cefotaxime, piperacillin-tazobactam and/or metronidazole) right after
223 they were admitted to our NICU. No infant was prescribed probiotics during the study. There was no
224 significant difference in gestational age ($p = 0.074$), birth weight ($p = 0.111$) or gender proportions ($p =$
225 0.822) among the three groups. The average age at diagnosis for both disease groups was 16 days and
226 there was no statistical difference between the groups ($p = 0.629$) (Table 1). Therefore, we assigned day
227 16 to discharge as early disease interval, day 4-8 as early pre-onset interval and day 9-15 as late pre-onset
228 interval for the control group.

229 **Longitudinal Microbiome Diversity of NEC and LOS patients**

230 To get an overview of gut microbiota in patients, we analyzed the microbial richness of the NEC and LOS
231 patients over time. Similar to the control group, the case groups showed a decreasing trend in observed
232 species (Sobs) from early post-partum stage (EPP) to early disease (ED) stage (Fig2 (A) control group, p
233 <0.01; (B) NEC group, $p = 0.044$; (C) LOS group, $p = 0.013$; Dataset S1, Sheet "Sobs" two way RM
234 ANOVA, $p < 0.0001$). The greatest decline in sobs was from early pre-onset (EPO) to late pre-onset
235 (LPO). However, the decrease in the disease groups was less significant than the control group (control
236 group $p = 0.0004$, NEC group $p = 0.18$, LOS group $p = 0.066$). The Sobs then stabilized from LPO
237 onward with no significant difference between adjacent time intervals.

238 Next, we analyzed gut microbiome evenness over time. Similar to Sobs, the Shannon indices decreased
239 significantly from the early post-partum (EPP) to early disease (ED) stage (Fig2(A) control group 2.768
240 to 1.004, $p = 0.04$; (B) NEC group, 3.141 to 0.578, $p = 0.01$; (C) LOS group, 2.641 to 0.470, $p = 0.01$).

241 Two way RM ANOVA showed significant Shannon index divergent among three groups before disease
242 onset (Dataset S1, sheet "Shannon", EPP to ED, $p = 0.0017$). Moreover, during early disease stage, the
243 Shannon indices were different among three groups (Fig4, facet "early disease", $p = 0.0037$), suggesting
244 that microbiota distortion may precede NEC and LOS onset. As diseases progressed, the NEC group
245 differed significantly with the LOS group during middle disease interval but insignificantly during late
246 disease interval (Fig4 facet "middle disease", $p = 0.034$; facet "late disease", $p = 0.750$). Upon alleviation
247 of both diseases, the Shannon indices rose back to the early pre-onset levels(Fig3 (B) NEC group. early
248 pre-onset at 1.925 vs. post disease at 1.320, $p = 0.79$; (C) LOS group, early pre-onset at 2.473 vs. post
249 disease at 1.463, $p = 0.16$).

Kinetics of Microbiome Composition

To compare the beta-diversity of the three groups over time, we applied Principal Component Analysis (PCoA) to weighted UniFrac distance matrix. Bacterial composition of three groups during early post-partum interval were the most similar compared with other time intervals, with the first principal coordinates accounted for 33.01%(Fig5 (A)). Then beta diversity continued to separate from one another. The first principal coordinate one (PC1) increased from 33.01% at the early post-partum to 35.23% at the early pre-onset stage, 38.36% at the late pre-onset stage and eventually reaching 42.32% at the early disease stage (Fig5 (B) to (D)). This continuous increase in beta-diversity suggested that the phylogenetic composition of the patients' microbiome started to deviate from the control group before the onset of diseases. As diseases progressed, the phylogenetic similarity between the NEC and the LOS disease groups diverged further and peaked at 59.53% in middle disease stage then came down gradually to 42.8% at post disease stage (Fig5 (E) to (G)). This trend in phylogenetic dissimilarity suggested that the microbiome composition of the NEC and LOS patients might have deviated from normal even before the onset of diseases. Also, the further separation between the NEC and the LOS groups could be a result of different treatment strategies.

Colonization Trend at The Genus Level

In the analyses of intestinal microbiome alpha(Fig2, Fig3, Fig4) and beta diversity(Fig5), detectable differences were observed among the three groups, especially during the transition from the LPO to ED stage. This indicated that the microbiota assembly differences between the case groups and control group. To further investigate which microbiota composition was correlated with the onset and/or progression of NEC and LOS, we tracked the longitudinal compositional changes in genera abundance. We filtered the genus of over 10% relative abundance among all samples and plotted relative abundance over time(Fig6).

At the early post-partum stage, all three groups showed high proportion of *Lactococcus*, *Bacillus* and *Pseudomonas*. However, ZIBR model the disease groups showed significantly higher OTUs that matched to *Bacillus* (NEC 15.05% and LOS 15.97% compared to 6.02% of control, $p = 0.032$) and *Solibacillus* (8.88% in NEC and 9.61% in LOS compared to 3.65% of control, $p = 0.047$) from the case groups (Dataset S2). Moreover, *Enterococcus* proportion (Fig6(B), purple area) was much higher in LOS patients (20.72%) than the normal controls (6.66%, Fig6(A), purple area) but almost absent in NEC patients (0.51%) (Fig6(B)). While all three groups showed increases in *Klebsiella* and *Escherichia-Shigella* and decrease in *Lactococcus* from EPP to ED, the rates of change were different among the three groups. The LOS group exhibited the most drastic changes, with a rapidly increase of *Klebsiella* (from 4.71% to 58.90%), *Escherichia-Shigella* (from 2.02% to 18.16%) and *Streptococcus* (from 1.22% to 12.68%)(Fig6(C)). Together, these three genera accounted for almost 100% of all bacteria (Fig6(C)). In addition, *Lactococcus* decreased more rapidly than the other groups, from 24.54% at EPP to 0.94% before LPO (Fig6(C) magenta area).

Besides, the increase of *Klebsiella* was the most minimal in NEC patients (Fig6(B) grey area, from 7.17% at EPP to 35.63% at ED). Moreover, a rapid surge of *Enterococcus*, *Staphylococcus* and *Streptococcus* from EPO to ED was only observed in NEC patients (Fig6(B), purple, dark and light blue area).

As NEC and LOS progressed with medical intervention, the genus in case groups underwent another round of drastic changes. Most notably, the fluctuation of *Enterococcus*, *Klebsiella*, *Staphylococcus* and *Peptoclostridium* during the disease stages (Fig6(B) and (C), stage ED to LD), which might be resultant from different healthcare strategies applied in two groups. Interestingly, as patients approached remission, the composition became more balanced and resembled more to that of the normal control, except for a higher level of *Clostridium*. In summary, relative to patients in the control group, we observed different patterns of temporal alterations in bacterial composition among NEC and LOS patients. Rapid changes in relative abundance of certain genera were revealed as early as early pre-onset of stages and were the most notable in LOS patients.

DISCUSSION

In this pilot study, we intend to investigate the etiopathology of NEC and LOS in Chinese preterm infants from the perspective of intestinal microbiota. We profiled the gut microbiome of NEC and LOS preterm infants from birth to death or discharge. Some of our findings are similar to previous larger-scale studies. Mainly, infants who developed NEC or LOS exhibit a different gut microbiota colonization pattern relative

303 to the controls. Case groups showed a decline in diversity, although to a different extent. Moreover, NEC
304 and LOS infants' intestines were prone to harbor potential pathogens prior to and after disease onsets,
305 such as *Enterococcus*, *Staphylococcus*, *Peptoclostridium* and *Streptococcus*. There were also findings
306 unique to this study will be discussed in the following paragraphs.

307 To our knowledge, few studies have analyzed stool bacterial alpha diversity in preterm infants as early
308 as three days after birth. Unexpectedly, within three days after birth (i.e., early post-partum interval), the
309 bacterial diversity of all three groups was the highest compared to the following stages. At this point, we
310 do not know if this high bacterial richness and evenness within three days of life are universal. More
311 data, especially from other countries, are needed to support this finding. After three days, the microbial
312 alpha diversity exhibited a declining trend in both disease groups and the control group. The number of
313 colonized species (sobs index) during this interval, in line with previous works(Mai et al., 2011, 2013),
314 remained similar before disease onset in both case and control groups, suggesting a minor role of bacterial
315 richness in the disease onset. Besides, a rapid decline in alpha diversity during the pre-onset stages was
316 observed. This could be resultant from the standardized antibiotic regimen right after admission into our
317 NICU. However, previous studies showed that the pervasive effect of antibiotics in reducing richness and
318 evenness arose only after 1 week to 2 months of administration(DiGiulio et al., 2008; Dethlefsen and
319 Relman, 2011; Fouhy et al., 2012; Greenwood et al., 2014; Tanaka et al., 2009). Thus, more research is
320 needed to identify if additional factor(s) is involved in this rapid decline.

321 The role of empiric prophylactic antibiotics in NEC or LOS is controversial. In animal models,
322 antibiotics eliminating Gram-negative bacteria enhance gut function and diminish mucosal injury to the
323 bowel thus preventing necrotizing enterocolitis or bacterial leakage into the bloodstream(Carlisle et al.,
324 2011; Jensen et al., 2013; Birck et al., 2015). In clinical practices, broad-spectrum antibiotics (the most
325 commonly prescribed medications in the NICU) are recommended to empirically prevent and treat both
326 NEC and LOS(Bury and Tudehope, 2001; Brook, 2008; Kimberlin et al., 2018). However, antibiotics
327 can further induce microbiome dysbiosis that may increase the risk of developing these diseases and
328 exacerbate the severity(Gibson et al., 2015; Kuppala et al., 2011; Martinez et al., 2017; Cantey et al., 2018).
329 Our results showed limited differences in bacterial diversity and composition between two case groups
330 and the control group despite continuously antibiotics administration. Although our results are in line
331 with the dysbiotic effect of antibiotics, there was not enough evidence to support whether antibiotics per
332 se induced or prevented NEC and LOS. Further studies are needed to confirm the causative relationships.

333 Furthermore, microbiota beta-diversity, which measures the phylogenetic similarity, drifted away
334 continuously among three groups before the onset of both diseases. These findings were inconsistent
335 with a previous study where the microbiota of NEC patients were shown to be similar to that of the
336 healthy controls at three days before onset(Mai et al., 2011). With regards to the LOS patients, it is also
337 inconsistent with the previous study where similar microbiota diversity was observed in LOS patients
338 during the disease and 72 hours before onset(Mai et al., 2013). These discrepancies could be a result
339 of differences in collection time points or differences in patients' demographics. Further studies are
340 necessary to address these issues. As the diseases progressed, the beta-diversity of the NEC group and
341 the LOS group separated further but converged again when diseases were alleviated. The exact cause
342 of this divergence was not clear. It could be related to different treatment strategies or some intrinsic
343 pathophysiology differences between the two diseases. Further studies should provide more insight.

344 In addition to bacterial diversity, we also tracked longitudinal changes in composition at the genus level
345 by plotting the relative abundance over time. Overall, the control group exhibited more stable microbiota
346 assembly, without drastic fluctuation in genus abundance and with less dominance of facultative anaerobes
347 such as *Enterococcus* and *Staphylococcus*(Gibson et al., 2015; La Rosa et al., 2014; Grier et al., 2017).
348 Based on our ZIBR model, an over-represented *Bacillus* and *Solibacillus* were detected during the pre-
349 onset stages in case groups. However, both genera diminished after disease onset suggesting that the initial
350 microbiota composition in preterms might contribute to their future health outcomes. Previous studies
351 also observed a surge in Proteobacteria phyla(Mai et al., 2013, 2011) preceding LOS and NEC onset. In
352 line with this, LOS patients in our cohort were also characterized by a higher abundance of *Klebsiella* in
353 their intestinal communities. On the contrary, NEC infants presented overgrowth of *Streptococcus* and
354 *Staphylococcus* (both belong to phyla *Firmicutes*) before disease onset. Further work is warranted to
355 identify specific genera and trends in association with the onset of NEC and/or LOS.

356 Diarrhea is one of the typical symptoms in NEC patients and *Peptoclostridium* is conventionally
357 regarded as a causative pathogen of hospital-acquired infectious diarrhea(Rodriguez et al., 2016; Pereira

et al., 2016). In our study, we identified a transient bloom of *Peptoclostridium* in late NEC stage that coincided with the diarrhea symptom, possibly explaining the mechanism of common diarrhea symptom in NEC patients. Moreover, mucosal-adhering bacteria such as *Enterococcus* and *Streptococcus* were highly represented in pediatric enterocolitis (Normann et al., 2013; Zhou et al., 2016). Consistent with this, NEC patients from our cohort exhibited a higher abundance of *Enterococcus* during disease stage.

In contrast, the composition of our LOS patient samples was very different from previous studies where *Enterobacteria* and *Staphylococcus* were identified as the most prevalent genera (Stewart et al., 2017; Mai et al., 2013). In our cohort of LOS patients, *Klebsiella* was the most dominated genus. LOS is frequently caused by organisms, mostly bacteria, that translocate from the intestinal tract to the bloodstream. Consistently, *Klebsiella* was detected in hemoculture in two out of two of our LOS patients (hemoculture was not performed for the third patient). In addition, *Klebsiella pneumoniae* is one of the most common causes of sepsis in preterm patients of our hospital (JL and LH personal observation), suggesting that the most dominant and eventually infectious bacteria may be more specific to the environment.

Another notable point in our cohort was almost absent *Bifidobacteria*, an anaerobe that can ferment milk oligosaccharides (Gomez-Gallego et al., 2016) and thus commonly detected among breastfed infants (Murphy et al., 2017). We speculate that this extremely low level in our cohort was due to the lack of breastfeeding in the sterile hospital environment, being nurtured in the sterile NICU environment, continuous administration of antibiotics or the combinations of the above. Although *Bifidobacteria* has been generally considered a probiotic that serves to protect neonates against necrotizing enterocolitis and systemic infection (Nakayama et al., 2003; Khodayar-Pardo et al., 2014; Hermansson et al., 2019), recent randomized controlled trials are showing paradoxical results (Hays et al., 2016; Singh et al., 2019). Further studies on the role of probiotics in optimizing preterm infants' microbiota should address their effectiveness in preventing NEC and LOS.

This study was limited to only one hospital in one specific region (Shanghai) in China so how far these findings can be extrapolated remains to be determined. In addition, our sample size was relatively small since both diseases are rare (Neu and Walker, 2011; Cohen-Wolkowicz et al., 2009). Among the 1148 preterm infants admitted from July 2013 to December 2014, only five developed NEC and seven developed LOS. Nevertheless, this pilot study has provided essential information about NEC and LOS preterm patients within the Chinese population and serves as a starting point for future investigations into the etiology and pathogenesis of both diseases in the nation.

CONCLUSIONS

In this longitudinal study, we used next generation-sequencing to profile the microbiota of 24 Chinese preterm infants from birth to discharge. Among them, four developed NEC and three developed LOS. To our knowledge, this is the first profiling of gut microbiota in NEC and LOS patients among the Asian population. Reduction in intestinal microbiota diversity and divergence of phylogenetic similarity from the control infants over time associated with both NEC and LOS onset. Overgrowth of potentially pathogenic genus *Enterococcus*, *Streptococcus* and *Peptoclostridium* were observed in NEC cases while *Klebsiella* was recognized as the dominant genus in LOS cases. In summary, our findings suggest that both NEC and LOS are dynamic processes involving abnormal microbiota assembly. This study is a starting point for further studying of microbial factors involved in preterm-associated complications in China. Accumulation of more data within China and perhaps from neighboring countries will allow us to build microbial signatures that can assist early diagnosis and development of novel treatment.

ACKNOWLEDGMENTS

We sincerely thank all the patients and their family in supporting this study. We extend our thanks to the medical and research staffs of the Shanghai Children's Medical Center. We also thank Ka Ming Pang, Arin Nam and Christina Meyer for critical reviews of this manuscript.

REFERENCES

Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., Kovatcheva-Datchary, P., Li, Y., Xia, Y., Xie, H., Zhong, H., et al. (2015). Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell host & microbe*, 17(5):690–703.

- 409 Bell, M. J., Ternberg, J. L., Feigin, R. D., Keating, J. P., Marshall, R., Barton, L., and Brotherton, T.
410 (1978). Neonatal necrotizing enterocolitis. therapeutic decisions based upon clinical staging. *Annals of*
411 *surgery*, 187(1):1.
- 412 Bezirtzoglou, E., Tsiotsias, A., and Welling, G. W. (2011). Microbiota profile in feces of breast-and
413 formula-fed newborns by using fluorescence in situ hybridization (fish). *Anaerobe*, 17(6):478–482.
- 414 Birck, M. M., Nguyen, D. N., Cilieborg, M. S., Kamal, S. S., Nielsen, D. S., Damborg, P., Olsen, J. E.,
415 Lauridsen, C., Sangild, P. T., and Thymann, T. (2015). Enteral but not parenteral antibiotics enhance
416 gut function and prevent necrotizing enterocolitis in formula-fed newborn preterm pigs. *American*
417 *Journal of Physiology-Heart and Circulatory Physiology*.
- 418 Blencowe, H., Cousens, S., Oestergaard, M. Z., Chou, D., Moller, A.-B., Narwal, R., Adler, A., Garcia,
419 C. V., Rohde, S., Say, L., et al. (2012). National, regional, and worldwide estimates of preterm birth
420 rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and
421 implications. *The Lancet*, 379(9832):2162–2172.
- 422 Bolger, A. M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for illumina sequence
423 data. *Bioinformatics*, 30(15):2114–2120.
- 424 Bouter, K. E., van Raalte, D. H., Groen, A. K., and Nieuwdorp, M. (2017). Role of the gut microbiome in
425 the pathogenesis of obesity and obesity-related metabolic dysfunction. *Gastroenterology*, 152(7):1671–
426 1678.
- 427 Brook, I. (2008). Microbiology and management of neonatal necrotizing enterocolitis. *American journal*
428 *of perinatology*, 25(02):111–118.
- 429 Bury, R. G. and Tudehope, D. (2001). Enteral antibiotics for preventing necrotizing enterocolitis in low
430 birthweight or preterm infants. *Cochrane Database of Systematic Reviews*, (1).
- 431 Cani, P. D. (2019). Severe obesity and gut microbiota: does bariatric surgery really reset the system? *Gut*,
432 68(1):5–6.
- 433 Cantey, J. B., Pyle, A. K., Wozniak, P. S., Hynan, L. S., and Sánchez, P. J. (2018). Early antibiotic
434 exposure and adverse outcomes in preterm, very low birth weight infants. *The Journal of pediatrics*,
435 203:62–67.
- 436 Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N.,
437 Pena, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010). Qiime allows analysis of high-throughput
438 community sequencing data. *Nature methods*, 7(5):335.
- 439 Carlisle, E. M., Poroyko, V., Caplan, M. S., Alverdy, J. A., and Liu, D. (2011). Gram negative bacteria
440 are associated with the early stages of necrotizing enterocolitis. *PloS one*, 6(3):e18084.
- 441 Cernada, M., Bäuerl, C., Serna, E., Collado, M. C., Martínez, G. P., and Vento, M. (2016). Sepsis in
442 preterm infants causes alterations in mucosal gene expression and microbiota profiles compared to
443 non-septic twins. *Scientific Reports*, 6(1):25497.
- 444 Chen, E. Z. and Li, H. (2016). A two-part mixed-effects model for analyzing longitudinal microbiome
445 compositional data. *Bioinformatics*, 32(17):2611–2617.
- 446 Cohen-Wolkowicz, M., Moran, C., Benjamin, D. K., Cotten, C. M., Clark, R. H., Benjamin Jr, D. K., and
447 Smith, P. B. (2009). Early and late onset sepsis in late preterm infants. *The Pediatric infectious disease*
448 *journal*, 28(12):1052.
- 449 Dethlefsen, L. and Relman, D. A. (2011). Incomplete recovery and individualized responses of the human
450 distal gut microbiota to repeated antibiotic perturbation. *Proceedings of the National Academy of*
451 *Sciences*, 108(Supplement 1):4554–4561.
- 452 Deweerdt, S. (2018). How baby’s first microbes could be crucial to future health. *Nature*, 555(7695):S18–
453 S19.
- 454 DiGiulio, D. B., Romero, R., Amogan, H. P., Kusanovic, J. P., Bik, E. M., Gotsch, F., Kim, C. J., Erez, O.,
455 Edwin, S., and Relman, D. A. (2008). Microbial prevalence, diversity and abundance in amniotic fluid
456 during preterm labor: a molecular and culture-based investigation. *PloS one*, 3(8):e3056.
- 457 Edgar, R. C. (2013). Uparse: highly accurate otu sequences from microbial amplicon reads. *Nature*
458 *methods*, 10(10):996.
- 459 Ficara, M., Pietrella, E., Spada, C., Della Casa Muttini, E., Lucaccioni, L., Iughetti, L., and Berardi, A.
460 (2018). Changes of intestinal microbiota in early life. *The Journal of Maternal-Fetal & Neonatal*
461 *Medicine*, pages 1–8.
- 462 Fouhy, F., Guinane, C. M., Hussey, S., Wall, R., Ryan, C. A., Dempsey, E. M., Murphy, B., Ross, R. P.,
463 Fitzgerald, G. F., Stanton, C., et al. (2012). High-throughput sequencing reveals the incomplete,

short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. *Antimicrobial agents and chemotherapy*, 56(11):5811–5820.

Gagliani, Nicola, Hu, Bo, Huber, Samuel, Elinav, and Richard (2014). The fire within: Microbes inflame tumors. *Cell*, 157(4):776–783.

Gibson, M. K., Crofts, T. S., and Dantas, G. (2015). Antibiotics and the developing infant gut microbiota and resistome. *Current opinion in microbiology*, 27:51–56.

Giongo, A., Gano, K. A., Crabb, D. B., Mukherjee, N., Novelo, L. L., Casella, G., Drew, J. C., Ilonen, J., Knip, M., Hyöty, H., et al. (2011). Toward defining the autoimmune microbiome for type 1 diabetes. *The ISME journal*, 5(1):82.

Gomez-Gallego, C., Garcia-Mantrana, I., Salminen, S., and Collado, M. C. (2016). The human milk microbiome and factors influencing its composition and activity. In *Seminars in Fetal and Neonatal Medicine*, volume 21, pages 400–405. Elsevier.

Greenwood, C., Morrow, A. L., Lagomarcino, A. J., Altaye, M., Taft, D. H., Yu, Z., Newburg, D. S., Ward, D. V., and Schibler, K. R. (2014). Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of enterobacter. *The Journal of pediatrics*, 165(1):23–29.

Grier, A., Qiu, X., Bandyopadhyay, S., Holden-Wiltse, J., Kessler, H. A., Gill, A. L., Hamilton, B., Huyck, H., Misra, S., Mariani, T. J., et al. (2017). Impact of prematurity and nutrition on the developing gut microbiome and preterm infant growth. *Microbiome*, 5(1):158.

Hays, S., Jacquot, A., Gauthier, H., Kempf, C., Beissel, A., Pidoux, O., Jumas-Bilak, E., Decullier, E., Lachambre, E., Beck, L., et al. (2016). Probiotics and growth in preterm infants: A randomized controlled trial, premapro study. *Clinical Nutrition*, 35(4):802–811.

Hermansson, H., Kumar, H., Collado, M. C., Salminen, S., Isolauri, E., and Rautava, S. (2019). Breast milk microbiota is shaped by mode of delivery and intrapartum antibiotic exposure. *Frontiers in nutrition*, 6.

Hintz, S. R., Kendrick, D. E., Stoll, B. J., Vohr, B. R., Fanaroff, A. A., Donovan, E. F., Poole, W. K., Blakely, M. L., Wright, L., Higgins, R., et al. (2005). Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. *Pediatrics*, 115(3):696–703.

Irrazábal, T., Belcheva, A., Girardin, S. E., Martin, A., and Philpott, D. J. (2014). The multifaceted role of the intestinal microbiota in colon cancer. *Molecular Cell*, 54(2):309–320.

Jacquot, A., Neveu, D., Aujoulat, F., Mercier, G., Marchandin, H., Jumas-Bilak, E., and Picaud, J.-C. (2011). Dynamics and clinical evolution of bacterial gut microflora in extremely premature patients. *The Journal of pediatrics*, 158(3):390–396.

Jensen, M. L., Thymann, T., Cilieborg, M. S., Lykke, M., Mølbak, L., Jensen, B. B., Schmidt, M., Kelly, D., Mulder, I., Burrin, D. G., et al. (2013). Antibiotics modulate intestinal immunity and prevent necrotizing enterocolitis in preterm neonatal piglets. *American Journal of Physiology-Heart and Circulatory Physiology*.

Jie, Z., Xia, H., Zhong, S. L., Feng, Q., Li, S., Liang, S., Zhong, H., Liu, Z., Gao, Y., and Zhao, H. (2017). The gut microbiome in atherosclerotic cardiovascular disease. *Nature Communications*, 8(1).

Johnson, T. J., Patel, A. L., Bigger, H. R., Engstrom, J. L., and Meier, P. P. (2014). Economic benefits and costs of human milk feedings: a strategy to reduce the risk of prematurity-related morbidities in very-low-birth-weight infants. *Advances in nutrition*, 5(2):207–212.

Johnson, T. J., Patel, A. L., Jegier, B. J., Engstrom, J. L., and Meier, P. P. (2013). Cost of morbidities in very low birth weight infants. *The Journal of pediatrics*, 162(2):243–249.

Jonsson, A. L. and Bäckhed, F. (2017). Role of gut microbiota in atherosclerosis. *Nature Reviews Cardiology*, 14(2):79.

Kassambara, A. (2017). ggpubr: “ggplot2” based publication ready plots. r package version 0.1. 6.

Khodayar-Pardo, P., Mira-Pascual, L., Collado, M., and Martinez-Costa, C. (2014). Impact of lactation stage, gestational age and mode of delivery on breast milk microbiota. *Journal of Perinatology*, 34(8):599.

Kimberlin, D. W. et al. (2018). *Red Book: 2018-2021 report of the committee on infectious diseases*. Number Ed. 31. American academy of pediatrics.

Korpela, K., Blakstad, E. W., Moltu, S. J., Strømmen, K., Nakstad, B., Rønnestad, A. E., Brække, K., Iversen, P. O., Drevon, C. A., and Vos, W. (2018). Intestinal microbiota development and gestational age in preterm neonates. *Scientific reports*, 8(1):2453.

519 Kuppala, V. S., Meinen-Derr, J., Morrow, A. L., and Schibler, K. R. (2011). Prolonged initial empirical
520 antibiotic treatment is associated with adverse outcomes in premature infants. *The Journal of pediatrics*,
521 159(5):720–725.

522 La Rosa, P. S., Warner, B. B., Zhou, Y., Weinstock, G. M., Sodergren, E., Hall-Moore, C. M., Stevens, H. J.,
523 Bennett, W. E., Shaikh, N., Linneman, L. A., et al. (2014). Patterned progression of bacterial populations
524 in the premature infant gut. *Proceedings of the National Academy of Sciences*, 111(34):12522–12527.

525 Liu, Y., Li, J., Jin, Y., Zhao, L., Zhao, F., Feng, J., Li, A., and Wei, Y. (2018). Splenectomy leads
526 to amelioration of altered gut microbiota and metabolome in liver cirrhosis patients. *Frontiers in*
527 *Microbiology*, 9.

528 Madan, J. C., Farzan, S. F., Hibberd, P. L., and Karagas, M. R. (2012a). Normal neonatal microbiome
529 variation in relation to environmental factors, infection and allergy. *Current opinion in pediatrics*,
530 24(6):753.

531 Madan, J. C., Salari, R. C., Saxena, D., Davidson, L., O'toole, G. A., Moore, J. H., Sogin, M. L.,
532 Foster, J. A., Edwards, W. H., Palumbo, P., et al. (2012b). Gut microbial colonisation in premature
533 neonates predicts neonatal sepsis. *Archives of Disease in Childhood-Fetal and Neonatal Edition*,
534 97(6):F456–F462.

535 Magoč, T. and Salzberg, S. L. (2011). Flash: fast length adjustment of short reads to improve genome
536 assemblies. *Bioinformatics*, 27(21):2957–2963.

537 Mai, V., Torrazza, R. M., Ukhanova, M., Wang, X., Sun, Y., Li, N., Shuster, J., Sharma, R., Hudak, M. L.,
538 and Neu, J. (2013). Distortions in development of intestinal microbiota associated with late onset sepsis
539 in preterm infants. *PloS one*, 8(1):e52876.

540 Mai, V., Young, C. M., Ukhanova, M., Wang, X., Sun, Y., Casella, G., Theriaque, D., Li, N., Sharma, R.,
541 Hudak, M., et al. (2011). Fecal microbiota in premature infants prior to necrotizing enterocolitis. *PloS*
542 *one*, 6(6):e20647.

543 Martinez, F. E., Ferri, W. A., Leone, C. R., De Almeida, M. F. B., Guinsburg, R., do Amaral Meneses, J.,
544 do Vale, M. S., Marba, S. T. M., De Carvalho, W. B., de Souza Rugolo, L. M. S., et al. (2017). Early
545 empiric antibiotic use is associated with delayed feeding tolerance in preterm infants: A retrospective
546 analysis. *Journal of pediatric gastroenterology and nutrition*, 65(1):107–110.

547 Mowitz, M. E., Dukhovny, D., and Zupancic, J. A. (2018). The cost of necrotizing enterocolitis in
548 premature infants. In *Seminars in Fetal and Neonatal Medicine*. Elsevier.

549 Murphy, K., Curley, D., O'Callaghan, T. F., O'Shea, C.-A., Dempsey, E. M., O'Toole, P. W., Ross, R. P.,
550 Ryan, C. A., and Stanton, C. (2017). The composition of human milk and infant faecal microbiota over
551 the first three months of life: a pilot study. *Scientific reports*, 7:40597.

552 Nakayama, M., Yajima, M., Hatano, S., Yajima, T., and Kuwata, T. (2003). Intestinal adherent bacteria
553 and bacterial translocation in breast-fed and formula-fed rats in relation to susceptibility to infection.
554 *Pediatric research*, 54(3):364.

555 Neu, J. and Walker, W. A. (2011). Necrotizing enterocolitis. *New England Journal of Medicine*,
556 364(3):255–264.

557 Normann, E., Fahlén, A., Engstrand, L., and Lilja, H. E. (2013). Intestinal microbial profiles in extremely
558 preterm infants with and without necrotizing enterocolitis. *Acta paediatrica*, 102(2):129–136.

559 Pereira, F. L., Júnior, C. A. O., Silva, R. O., Dorella, F. A., Carvalho, A. F., Almeida, G. M., Leal, C. A.,
560 Lobato, F. C., and Figueiredo, H. C. (2016). Complete genome sequence of peptoclostridium difficile
561 strain z31. *Gut pathogens*, 8(1):11.

562 Pickering, L. K., Baker, C. J., Kimberlin, D. W., et al. (2012). *Red Book, (2012): Report of the Committee*
563 *on Infectious Diseases*. Am Acad Pediatrics.

564 Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D., and R Core Team (2018). *nlme: Linear and Nonlinear*
565 *Mixed Effects Models*. R package version 3.1-137.

566 Pronovost, G. N. and Hsiao, E. Y. (2019). Perinatal interactions between the microbiome, immunity, and
567 neurodevelopment. *Immunity*, 50(1):18–36.

568 Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., and Glöckner, F. O.
569 (2012). The silva ribosomal rna gene database project: improved data processing and web-based tools.
570 *Nucleic acids research*, 41(D1):D590–D596.

571 Rao, S. C., Srinivasjois, R., and Moon, K. (2016). One dose per day compared to multiple doses per day
572 of gentamicin for treatment of suspected or proven sepsis in neonates. *Cochrane database of systematic*
573 *reviews*, (12).

574 Rodriguez, C., Van Broeck, J., Taminiau, B., Delmée, M., and Daube, G. (2016). Clostridium difficile
575 infection: early history, diagnosis and molecular strain typing methods. *Microbial pathogenesis*,
576 97:59–78.

577 Rosenbaum, M., Knight, R., and Leibel, R. L. (2015). The gut microbiota in human energy homeostasis
578 and obesity. *Trends in Endocrinology & Metabolism*, 26(9):493–501.

579 Sampson, T. R. and Mazmanian, S. K. (2015). Control of brain development, function, and behavior by
580 the microbiome. *Cell Host & Microbe*, 17(5):565–576.

581 Savage, J. H., Lee-Sarwar, K. A., Sordillo, J., Bunyavanich, S., Zhou, Y., O’connor, G., Sandel, M.,
582 Bacharier, L. B., Zeiger, R., Sodergren, E., et al. (2018). A prospective microbiome-wide association
583 study of food sensitization and food allergy in early childhood. *Allergy*, 73(1):145–152.

584 Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A.,
585 Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009). Introducing mothur: open-source, platform-
586 independent, community-supported software for describing and comparing microbial communities.
587 *Applied and environmental microbiology*, 75(23):7537–7541.

588 Schwiertz, A., Gruhl, B., Löbnitz, M., Michel, P., Radke, M., and Blaut, M. (2003). Development of the
589 intestinal bacterial composition in hospitalized preterm infants in comparison with breast-fed, full-term
590 infants. *Pediatric research*, 54(3):393.

591 Sears, C. L. and Garrett, W. S. (2014). Microbes, microbiota, and colon cancer. *Cell Host & Microbe*,
592 15(3):317–328.

593 Shah, J., Jefferies, A. L., Yoon, E. W., Lee, S. K., Shah, P. S., Network, C. N., et al. (2015). Risk factors
594 and outcomes of late-onset bacterial sepsis in preterm neonates born at 32 weeks’ gestation. *American
595 journal of perinatology*, 32(07):675–682.

596 Sharon, U., Alain, S., Prakeshkumar, S., David, M., and O’Connor, D. L. (2015). Gut microbiota of the
597 very-low-birth-weight infant. *Pediatric Research*, 77(1-2):205.

598 Shin, H., Pei, Z., Martinez, K. A., Rivera-Vinas, J. I., Mendez, K., Cavallin, H., and Dominguez-Bello,
599 M. G. (2015). The first microbial environment of infants born by c-section: the operating room
600 microbes. *Microbiome*, 3(1):59.

601 Singh, B., Shah, P. S., Afifi, J., Simpson, C. D., Mitra, S., Dow, K., and El-Naggar, W. (2019). Probiotics
602 for preterm infants: A national retrospective cohort study. *Journal of Perinatology*, page 1.

603 Stewart, C. J., Ajami, N. J., O’Brien, J. L., Hutchinson, D. S., Smith, D. P., Wong, M. C., Ross, M. C.,
604 Lloyd, R. E., Doddapaneni, H., Metcalf, G. A., et al. (2018). Temporal development of the gut
605 microbiome in early childhood from the teddy study. *Nature*, 562(7728):583.

606 Stewart, C. J., Embleton, N. D., Marrs, E. C. L., Smith, D. P., Fofanova, T., Nelson, A., Skeath, T., Perry,
607 J. D., Petrosino, J. F., and Berrington, J. E. (2017). Longitudinal development of the gut microbiome
608 and metabolome in preterm neonates with late onset sepsis and healthy controls. *Microbiome*, 5(1):75.

609 Stokholm, J., Blaser, M. J., Thorsen, J., Rasmussen, M. A., Waage, J., Vinding, R. K., Schoos, A.-M. M.,
610 Kunø, A., Fink, N. R., Chawes, B. L., et al. (2018). Maturation of the gut microbiome and risk of
611 asthma in childhood. *Nature communications*, 9(1):141.

612 Stoll, B. J., Hansen, N. I., Bell, E. F., Walsh, M. C., Carlo, W. A., Shankaran, S., Laptook, A. R., Sánchez,
613 P. J., Van Meurs, K. P., Wyckoff, M., et al. (2015). Trends in care practices, morbidity, and mortality of
614 extremely preterm neonates, 1993-2012. *Jama*, 314(10):1039–1051.

615 Tanaka, S., Kobayashi, T., Songjinda, P., Tateyama, A., Tsubouchi, M., Kiyohara, C., Shirakawa, T.,
616 Sonomoto, K., and Nakayama, J. (2009). Influence of antibiotic exposure in the early postnatal period
617 on the development of intestinal microbiota. *FEMS Immunology & Medical Microbiology*, 56(1):80–87.

618 Tang, W. W., Kitai, T., and Hazen, S. L. (2017). Gut microbiota in cardiovascular health and disease.
619 *Circulation research*, 120(7):1183–1196.

620 Tarr, P. I. and Warner, B. B. (2016). Gut bacteria and late-onset neonatal bloodstream infections in preterm
621 infants. In *Seminars in Fetal and Neonatal Medicine*, volume 21, pages 388–393. Elsevier.

622 Vatanen, T., Franzosa, E. A., Schwager, R., Tripathi, S., Arthur, T. D., Vehik, K., Lernmark, Å., Hagopian,
623 W. A., Rewers, M. J., She, J.-X., et al. (2018). The human gut microbiome in early-onset type 1 diabetes
624 from the teddy study. *Nature*, 562(7728):589.

625 Vatanen, T., Kostic, A., D’Hennezel, E., Siljander, H., Franzosa, E., Yassour, M., Kolde, R., Vlamakis, H.,
626 Arthur, T., and Hämäläinen, A. M. (2016). Variation in microbiome lps immunogenicity contributes to
627 autoimmunity in humans. *Cell*, 165(4):842–853.

628 Vogelzang, A., Guerrini, M. M., Minato, N., and Fagarasan, S. (2018). Microbiota—an amplifier of

629 autoimmunity. *Current opinion in immunology*, 55:15–21.

630 Wang, Q., Garrity, G. M., Tiedje, J. M., and Cole, J. R. (2007). Naive bayesian classifier for rapid
631 assignment of rna sequences into the new bacterial taxonomy. *Applied and environmental microbiology*,
632 73(16):5261–5267.

633 Wang, R., Xiao, Y., Lv, F., Hu, L., Wei, L., Yuan, Z., and Lin, H. (2018). Bacterial community structure
634 and functional potential of rhizosphere soils as influenced by nitrogen addition and bacterial wilt disease
635 under continuous sesame cropping. *Applied Soil Ecology*, 125:117–127.

636 Warner, B. B., Deych, E., Zhou, Y., Hall-Moore, C., Weinstock, G. M., Sodergren, E., Shaikh, N.,
637 Hoffmann, J. A., Linneman, L. A., Hamvas, A., Khanna, G., Rouggly-Nickless, L. C., Ndao, I. M.,
638 Shands, B. A., Escobedo, M., Sullivan, J. E., Radmacher, P. G., Shannon, W. D., and Tarr, P. I. (2016).
639 Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: A prospective
640 case-control study. *The Lancet*, 387(10031):1928–1936.

641 Wickham, H. (2016). *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York.

642 Winer, D. A., Luck, H., Tsai, S., and Winer, S. (2016). The intestinal immune system in obesity and
643 insulin resistance. *Cell metabolism*, 23(3):413–426.

644 Xiao, N. (2018). *ggsci: Scientific Journal and Sci-Fi Themed Color Palettes for 'ggplot2'*. R package
645 version 2.9.

646 Yatsunenkov, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M.,
647 Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012). Human gut microbiome viewed across
648 age and geography. *nature*, 486(7402):222.

649 Zhou, Y., Chen, H., He, H., Du, Y., Hu, J., Li, Y., Li, Y., Zhou, Y., Wang, H., Chen, Y., et al. (2016).
650 Increased enterococcus faecalis infection is associated with clinically active crohn disease. *Medicine*,
651 95(39).

652 Zhou, Y., Shan, G., Sodergren, E., Weinstock, G., Walker, W. A., and Gregory, K. E. (2015). Longitudinal
653 analysis of the premature infant intestinal microbiome prior to necrotizing enterocolitis: a case-control
654 study. *PloS one*, 10(3):e0118632.

655 Zmora, N., Suez, J., and Elinav, E. (2019). You are what you eat: diet, health and the gut microbiota.
656 *Nature Reviews Gastroenterology & Hepatology*, 16(1):35–56.

657 Zonnenberg, I., van Dijk-Lokkart, E., van den Dungen, F., Vermeulen, R., and van Weissenbruch, M.
658 (2019). Neurodevelopmental outcome at 2 years of age in preterm infants with late-onset sepsis.
659 *European journal of pediatrics*, pages 1–8.